Funding Correction Issued for Pharmacological Study Backed by South Korean Grants

Academic transparency requires precise accounting, and a recent administrative update has brought clarity to the financial backers behind a prominent study published in Frontiers in Pharmacology. Researchers working on complex biotechnological and pharmacological investigations often rely on multifaceted grants to sustain their laboratory experiments, animal models, and data collection phases. When administrative errors occur in the initial publishing records, journals issue formal corrections to ensure proper credit is given to public funding agencies and institutional partners.

Funding Corrections Reveal Broad Institutional Backing for Pharmacological Research

The updated financial disclosure, published in Frontiers in Pharmacology, highlights vital support from several major South Korean governmental and research bodies. Specifically, the National Research Foundation of Korea provided crucial grants through the Ministry of Science and ICT, designated under project numbers RS-2025-24534393 and RS-2023-00217595, directed toward researcher Y.H.P. These specific grants form part of a broader strategy by the government to foster advanced biomedical discoveries and therapeutic innovations.

In addition to science and ICT funding, the team received essential backing from the Korea Health Technology R&D Project. This initiative operates through the Korea Health Industry Development Institute and receives financial resources from the Ministry of Health and Welfare in the Republic of Korea. These specific health-focused grants, cataloged under project identifiers RS-2022-KH130309 and RS-2024-00407544, help bridge the gap between early laboratory discoveries and translational medicine.

How International Collaboration Shapes Modern Biotechnology Projects

Modern biotechnology frequently transcends national borders, relying on international partnerships to share technical expertise and facilitate fieldwork. The corrected documentation outlines important contributions from the National Institute for Research in Rural Engineering, Water and Forests, commonly known as INRGREF, located in Tunisia. This institution played a pivotal role in facilitating the practical implementation of the study on the ground.

Furthermore, the Korea Research Institute of Bioscience and Biotechnology, frequently abbreviated as KRIBB, partnered directly with INRGREF through a formal collaborative research agreement. KRIBB provided direct financial support for the investigation, while INRGREF managed the on-site logistical framework required to execute the research protocol successfully. Such cross-continental cooperation allows research teams to combine specialized laboratory technology with unique regional resources and environmental insights.

Academic Governance and the Importance of Accurate Metadata

Maintaining the integrity of scientific literature demands rigorous oversight from editorial boards and publishing offices. The correction notice was formally approved by the Frontiers Editorial Office, based in Switzerland, following a comprehensive review of the original manuscript metadata. While funding corrections do not alter the underlying experimental data, biological observations, or analytical conclusions of a study, they remain critical for legal compliance, ethical transparency, and academic accountability.

Publishers emphasize that all scientific claims, therapeutic evaluations, and hypotheses expressed within such studies remain exclusively those of the individual authors. These views do not necessarily reflect the official policies of affiliated universities, funding agencies, corporate manufacturers, or the journal publisher itself. By correcting the financial disclosures, the scientific community ensures that future researchers can accurately track the provenance of the work and verify the institutional networks supporting global biotechnology advancements.

The research was published in Frontiers in pharmacology on October 24, 2026.